Evidence map›Paper›PMID 37259305›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Selective 5-HT

Anna Partyka, Katarzyna Górecka, Joanna Gdula-Argasińska, Natalia Wilczyńska-Zawal, Magdalena Jastrzębska-Więsek, Anna Wesołowska

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anna PartykaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0001-9606-5228
Katarzyna GóreckaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.
Joanna Gdula-ArgasińskaDepartment of Radioligands, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0003-3501-8350
Natalia Wilczyńska-ZawalDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.
Magdalena Jastrzębska-WięsekDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0002-5388-1214
Anna WesołowskaDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.ORCID 0000-0003-2383-3278
Jagiellonian University · PL

Funding

National Science Center UMO-2015/19/B/NZ7/00227
6 · The paper itself

Abstract

It is estimated that in patients taking antipsychotic drugs (APDs), metabolic syndrome occurs 2-3 times more often than in the general population. It manifests itself in abdominal obesity, elevated glucose concentration, and dyslipidemia. Despite the high prevalence of this disorder, only a small percentage of patients receive appropriate and effective treatment, and none of the available methods for preventing or treating APD-induced metabolic side effects is satisfactory. A promising supplement to antipsychotic therapy appears to be ligands of the serotonin 6 (5-HT

Indexed as

5-HT6 receptoradiponectinantipsychotic drugsghrelinhyperglycemiainsulinleptinlipid profilemetabolic disordersweight gain

Identifiers

PMID37259305
PMCPMC9967858
OpenAlexW4317725693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.